The American Heart Association reports that cardiovascular disease claims 2,300 lives each day in the United States. Over the past decade, physicians and scientists have worked feverishly to find ways to combat the various physiological and behavioral risk factors associated with cardiovascular disease. The one and a half day symposium will feature lectures and discussions by a distinguished faculty, providing up-to-date information on the current status and future direction of cardiovascular medicine, surgery and research. Faculty will highlight recent progress in the diagnosis and treatment of cardiovascular disease as well as present new therapeutic modalities.
Target Audience
The audience for this continuing medical education activity includes cardiologists, cardiovascular surgeons, internists with an interest in cardiology and clinical researchers.
Learning Objectives
At the conclusion of this symposium, participants should be able to -
-
Discuss recent scientific advances in lipid management and the use of statins for acute and chronic coronary artery disease.
-
Review newer pharmacologic platforms for ST elevation MI.
-
Describe advances in the medical and interventional treatment of unstable angina and non-Q wave MI.
-
Determine the appropriate use of CT and MRI/MRA for diagnosing cardiovascular disease.
-
Summarize recent findings of clinical trials and their indications for current and future medical therapy for heart failure.
-
Discuss latest findings related to pathogenesis of hypertrophic cardiomyopathy and its treatment.
-
Cite new surgical options with robotic surgery, and its role in modern-day surgical practice.
-
Assess the latest surgical devices available to treat acute, decompensated heart failure patients.
-
Recognize the potential therapeutic options with stem cell therapy for cardiovascular disease including congestive heart failure.
-
Highlight new advances in electrophysiology, including biventricular pacing, defibrillation, and ablation.
-
Explain the role of inflammation and inflammatory markers in the current view of atherosclerotic disease.
-
Discuss how genes are being used to identify patients at risk for premature MIs.
-
Identify specific PCI characteristics that are associated with a higher risk of very late complications, including stent thrombosis.
-
Discuss the use of stem cell therapy in the regeneration of damaged heart tissue.
Faculty
Eric Boerwinkle, PhD
Benjamin Cheong, MD
William E. Cohn, MD
R. David Fish, MD
O.H. Frazier, MD
Peter Jones, MD
Peter Libby, MD
Douglas L. Mann, MD
A.J. Marian, MD
Ali Massumi, MD
Emerson C. Perin, MD, PhD
James T. Willerson, MD
James M. Wilson, MD
Edward T.H. Yeh, MD
Program Schedule
Friday December 4, 2009
1:00 p.m. Welcome and Introduction
1:15 p.m. Sessions Begin
5:30 p.m. Adjourn
Saturday December 5, 2009
8:00 a.m. Continental Breakfast
8:30 a.m. Sessions Begin
11:00 a.m. Ray C. Fish Celebration Luncheon
12:15 p.m. Sessions Resume
2:15 p.m. Final Comments and Adjourn
See program brochure for details.
|
